Vancouver-based health technology firm Molecular You has secured $5 million in Series A funding to expand its comprehensive biomarker testing platform. The company specializes in analyzing 250 different biomarkers through blood samples to assess individuals’ risk factors for various health conditions including cardiovascular disease, diabetes, dementia, and irritable bowel syndrome.
The testing service, which includes at-home blood draws, is available directly to U.S. consumers for $1,099 and through partner clinics in Canada for $1,149. While not currently covered by insurance, the company aims to significantly expand its capabilities by increasing its biomarker panel to over 800 markers using advanced multi-omic assays that examine RNA transcripts, proteins, and metabolites.
“This funding will allow us to expand our customer reach across North America in both consumer and clinical channels, while enhancing our platform’s analytical and predictive capabilities,” said CEO Jim Kean in an announcement of the investment.
Molecular You emerged in 2014 as an offshoot of Canada’s Personalized Medicine Initiative and now employs 25 people. The company is part of the growing longevity technology sector, which has attracted $1.8 billion in investments from 2021 through Q1 2025, according to PitchBook data. This sector has evolved from focusing primarily on age-related conditions to examining biological factors connected to aging and lifespan extension.
The Series A round was spearheaded by Voloridge Health, with additional participation from Dynamic Leap and other investors. This brings Molecular You’s total funding to $29 million since its inception. The company’s leadership team includes co-founders Rob Fraser as president and chief scientist, David Wishart as chief informatics officer, Christoph Borchers as chief lab analytics officer, Haiyan Yang as vice president of operations, and Ash Anwar as senior director of data science.
Looking ahead, the company plans to broaden its analysis capabilities to potentially include certain types of cancer detection through its enhanced biomarker panel. This expansion aligns with the broader longevity sector’s development, which includes various services such as full-body MRIs, genomic sequencing, plasma exchange, and coronary artery imaging.